Open Demat Account

50years
50 Years
of Trust & Legacy
₹0 AMC
for First Year
₹0 Brokerage
on Delivery, Intraday, Currency and NSE F&O
left-arrow
Fundamentals
Financials
Shareholding
Resistance/Support
Delivery and Volume
About
Management
News
Similar Stocks
right-arrow

ERIS Lifesciences Ltd Performance

Today's Low
855.00
arrowIcon
Today's High
879.90
52 Wk Low
602.00
arrowIcon
52 Wk High
971.90


Open

860

Traded Value (Cr)

13.08 Cr

Prev. Close

870.3

VWAP

870.23

Volume

1,20,833

Face Value

1

ERIS Lifesciences Ltd Fundamentals

Market Cap
₹ 11,482 Cr
P/E Ratio (TTM)
29.72
P/B Ratio
4.76
Debt to Equity
0.34
ROE
15.99 %
EPS (TTM)
28.40
Dividend Yield
0.87%
Book Value
177.26

Click here to know more about Fundamentals

ERIS Lifesciences Ltd Financials

ERIS Lifesciences Ltd Financials

ERIS Lifesciences Ltd Shareholding Pattern

Held By Dec 2023 Sep 2023 Jun 2023 Mar 2023
Promoters 54.90 % 54.91 % 52.86 % 52.86 %
Retail 15.67 % 15.47 % 22.07 % 21.66 %
Mutual Funds 13.85 % 13.86 % 10.27 % 9.64 %
FII 13.14 % 13.20 % 13.78 % 14.86 %
Others 2.44 % 2.56 % 1.02 % 0.98 %

Promoters

54.90%

Retail

15.67%

Mutual Funds

13.85%

FII

13.14%

Others

2.44%

Promoters

54.91%

Retail

15.47%

Mutual Funds

13.86%

FII

13.20%

Others

2.56%

Promoters

52.86%

Retail

22.07%

Mutual Funds

10.27%

FII

13.78%

Others

1.02%

Promoters

52.86%

Retail

21.66%

Mutual Funds

9.64%

FII

14.86%

Others

0.98%

Resistance and Support

₹841.97

PIVOT

resistance-arrow
Resistance
First Resistance₹846.783
Second Resistance₹850.617
Third Resistance₹855.433
support-arrow
Support
First Resistance₹838.133
Second Resistance₹833.317
Third Resistance₹829.483
RSI70.012
MACD6.653
ADX24.229
CCI244.244

Delivery and Volume

PeriodDelivery Volume Traded Volume Delivery Volume %
Day120,833126,66484.74
Week98,43595,96577.61
1 Month78,90759,94967.30
6 Months120,83377,78664.37

About ERIS Lifesciences Ltd

Eris Lifesciences Limited was incorporated on January 25, 2007. Subsequently, the name of the company was changed to 'Eris Lifesciences Private Limited' on February 9, 2007. Further, the Company was converted into a Public Limited cCompany and the name was changed to 'Eris Lifesciences Limited' on February 2, 2017. The Company has a manufacturing plant in Guwahati, Assam and is presently engaged in manufacturing and marketing of pharmaceutical products. It has presence in high growth chronic, sub chronic and acute therapeutic areas that require high intervention of specialist and super specialist doctors. Apart from this, it has a portfolio of 112 Mother Brands across therapy areas. The company develops, manufactures and commercializes branded pharmaceutical products in selected therapeutic areas within the chronic and acute categories of the Indian Pharmaceutical Market (IPM), such as: cardiovascular; anti-diabetics; vitamins; gastroenterology; and anti-infective. Its focus has been on developing products in the chronic and acute categories which are linked to lifestyle related disorders. Its operations are supported by a distribution network of 22 Sales depots, 2,059 Stockists and more than 5,00,000 retail chemists. In 2007, the company launched 'Eris' division focused on cardiology and diabetes segment. In 2008, the company launched 'Nikkos' division focused on gastroenterology and orthopedics segment. In 2009, the company launched 'Adura' division focused on cardiology and diabetes segment. In 2011, the company launched 'Montana' division focused on gynecology and pediatrics segment. In 2012, the company launched 'Inspira' division focused on cardiology segment. In 2014, the company launched 'Victus' division focused on anti-diabetes segment. During the year, the company set up manufacturing facility at Assam. In 2015, the company launched 'Eris 2' division focused on pain management segment. In 2016, the company acquired 40 registered and unregistered trademarks from Amay Pharmaceuticals Private Limited (now, Aprica Pharmaceuticals Private Limited). During the year, the company acquired 100% of the outstanding equity shares of Aprica Healthcare Private Limited and 75.48% of the outstanding equity shares of Kinedex Healthcare Private Limited. In 2017, the company acquired the trademarks UNION', REUNION' and BON UNION'. Eris Lifesciences made its debut on the secondary equity market on 29 June 2017. The stock debuted at Rs 612 on BSE compared with the initial public offer (IPO) price of Rs 603. In October 2017, Eris Lifesciences Ltd (Eris) acquired the entire shareholding of UTH Healthcare Ltd (UTH) for an all-cash consideration of Rs 129 million. UTH is largely engaged in the segments of obesity, diabetes, gestational diabetes mellitus, maternal nutrition, and cardio-vascular diseases. The acquisition provides Eris with a portfolio of products that complement its other offerings. In December 2017, Eris Lifesciences Ltd (Eris) acquired the Indian branded formulations business of Strides Shasun Ltd (Strides) for an aggregate cash consideration of Rs 5000 crore. With this acquisition, Eris acquired the marketing and distribution rights for India for 130+ brands in the Neurology, Psychiatry, Nutraceuticals and Women Healthcare therapy areas. The Indian branded formulations business being divested by Strides had sales of Rs 181 crore for FY 2017. During the year 2018, capital expenditure amounted to Rs 242.69 million. Additionally, consideration of Rs. 5,061.52 million was paid towards business acquisition. During the year 2018, UTH Healthcare Limited and Eris Healthcare Private Limited (earlier known as Strides Healthcare Private Limited) became subsidiaries of the Company. As on March 31, 2019, the Company has 5 subsidiaries out of which 4 are wholly owned subsidiaries. During the year 2019, capital expenditure amounted to Rs 374.15 million. Additionally, consideration of Rs. 107.22 million was paid towards business acquisition. In April 2019, the Company acquired the remaining shares of Kinedex Healthcare Private Limited, thereby making it a wholly owned subsidiary. It launched new business divisions, ErisART, Nutriverse, Aspire, Oncosciences, Filix, and Allure. A newly constructed facility for soft-gel was added in the year 2019 with total production capacity of 75 mn units. An extended facility has been included for supplements and Nutraceuticals with an additional capacity of 60 mn tablets, 41 mn capsules and 4 mn sachets. In December 2019, it launched Zomelis, after acquiring the trademark from Novartis. As on March 31, 2020, the Company has 5 five wholly owned subsidiaries. During the year 2020, the Company has acquired the remaining shares of Kinedex Healthcare Private Limited, thereby making it a wholly owned subsidiary. Eris Healthcare Private Limited has incorporated subsidiary company 'Eris Pharmaceuticals Private Limited' on 2nd, June 2020. In Q3 FY 20, the Company launched Rariset, under their in-licensing agreement with Pharmanutra S.P.A for their patent protected Sucrosomial Iron. As on March 31, 2021, the Company has 3 three wholly owned and 1 other than wholly owned subsidiaries. During the year 2021, two Companies namely Aprica Healthcare Limited and Eris Therapeutics Private Limited ceased to be subsidiaries of the Company. Eris Healthcare Private Limited, wholly owned subsidiary of the Company, had incorporated a subsidiary company 'Eris Pharmaceuticals Private Limited' on 2nd June, 2020. In FY'21. the Company strengthened portfolio with Gluxit, its Dapagliozin brand in the strategically important SGLT 2 segment launched in October'20. Eritel and LNBloc maintained ranks in their respective segments and made a debut in fast-growing anti-thrombotics segment through the launch of Rivalto, Rivaroxaban offering. It fortified portfolio with the launch of ZACD, an immunity-enhancing formulation and added Bricet to its portfolio. Of the top 4 Mother Brands - Serlift, Desval ER, Sonaxa and Levroxa while Serlift, and Desval ER maintained theirranks in their respective segments. As on March 31, 2022, the Company has 3 wholly-owned subsidiaries and 2 other than wholly owned subsidiaries. In 2022, Eris Therapeutics Limited, wholly owned subsidiary of the Company, was incorporated on 23rd June, 2021. The Company's wholly owned subsidiary Eris M.J. Biopharm Private Limited (Formerly known as Kinedex Healthcare Private Limited) issued fresh shares through private placement, pursuant to which Eris holding had 70% in Eris M.J. Biopharm Private Limited. It launched human insulin through subsidiary, Eris MJ Biopharm Ltd. In Q4 FY 22, it launched Xsulin in the forms of vials and cartridges. During the year 2023, the Company acquired 100% stake in Eris Oaknet Healthcare Private Limited in 2023. It launched Glura, a DPP4 Inhibitor. In Jan'23, it acquired 9 Derma brands from Glenmark for Rs 3,400 million and in Mar'23, it acquired 9 Cosmetology brands from Dr Reddy's for Rs 2,750 million. In 2022-23, Eris Healthcare Private Limited, a wholly owned subsidiary, demerged its Acquired Brands business to the Aprica Healthcare Limited, a wholly owned subsidiary, through a Scheme of Arrangement effective December 23, 2022.

Managing Director

Amit Indubhushan Bakshi

Founded

2007

NSE Symbol

ERIS

ERIS Lifesciences Ltd Management

NameDesignation
Amit Indubhushan BakshiCMD & Executive Director
Kaushal Kamlesh ShahWTD & Executive Director
Inderjeet Singh NegiWTD & Executive Director
Krishnakumar VaidyanathanExecutive Director / WTD / Chi
Sujesh VasudevanIndependent Non Exe. Director
Prashant GuptaIndependent Non Exe. Director
Rajeev Narotam DalalIndependent Non Exe. Director
Kalpana UnadkatIndependent Non Exe. Director

ERIS Lifesciences Ltd News

Board of Eris Lifesciences approves acquisition of branded formulations biz of Biocon Biologics
Also approved acquisition of 19% stake in Swiss Parenterals
ERIS Lifesciences consolidated net profit rises 0.86% in the December 2023 quarter
Sales rise 15.71% to Rs 483.48 crore
ERIS Lifesciences announces board meeting date
On 13 February 2024
Volumes jump at ERIS Lifesciences Ltd counter
ERIS Lifesciences Ltd witnessed volume of 9.23 lakh shares by 10:48 IST on BSE, a 13.19 times surge over two-week average daily volume of 69945 shares
Volumes jump at ERIS Lifesciences Ltd counter
ERIS Lifesciences Ltd saw volume of 9.57 lakh shares by 14:14 IST on NSE, a 14.95 fold spurt over two-week average daily volume of 64007 shares
ERIS Lifesciences allots 5,032 equity shares under ESOP
ERIS Lifesciences acquires Biocon Biologics' Nephrology and Dermatology biz
Eris Lifesciences avails term loan of Rs 280 cr from Citi Bank
To fund acquisition of Biocon Biologics's Nephrology and Dermatology biz in India
ERIS Lifesciences consolidated net profit rises 2.60% in the September 2023 quarter
Sales rise 9.92% to Rs 500.52 crore
ERIS Lifesciences schedules board meeting
On 8 November 2023

Similar Stocks

CompanyMarket CapMarket PriceP/E Ratio
SUNPHARMA₹ 3,65,370 Cr
₹ 1,522.80
(0.42 %)
88.68
CIPLA₹ 1,08,655 Cr
₹ 1,345.75
(-0.12 %)
33.03
DRREDDY₹ 99,137 Cr
₹ 5,942.85
(-0.24 %)
24.91
DIVISLAB₹ 97,472 Cr
₹ 3,671.70
(-1.00 %)
71.41
MANKIND₹ 93,635 Cr
₹ 2,337.45
(-2.43 %)
56.69

ERIS Lifesciences Ltd FAQ

By opening a demat account and having your KYC papers confirmed online, you may simply purchase ERIS Lifesciences Ltd shares in BlinkX

The share price of any stock is volatile and changes during the day due to a variety of variables. ERIS Lifesciences Ltd's share price is ₹875.10 as of April 19, 2024

ERIS Lifesciences Ltd's P/E ratio is 29.72 times as of April 19, 2024.

ERIS Lifesciences Ltd's most recent financial reports indicate a price-to-book ratio of 4.76, showing the company's stock market valuation in relation to the value of its real assets.

Market capitalisation, often known as market cap, is the market value of all outstanding shares of a publicly listed corporation. ERIS Lifesciences Ltd's market is 11,482 Cr as on April 19, 2024.

The current financial records of ERIS Lifesciences Ltd show a 15.99% ROE, showing great financial performance and effective capital utilisation, making it a significant statistic for investors.

The 52-week high/low price of a ERIS Lifesciences Ltd stock is the highest and lowest price at which it has traded over that period (about one year) and is used as a technical indicator. ERIS Lifesciences Ltd's 52-week high and low as of April 19, 2024 are ₹879.9 and ₹855 respectively.

As of the Dec 2023 quarter, the promoter shareholding in ERIS Lifesciences Ltd stands at 54.90%. During the same period, Institutional Investors have shown a slight decrease in their holdings, dropping from 13.20% to 13.14%.